Sotera Health (NASDAQ:SHC – Get Free Report) and Repligen (NASDAQ:RGEN – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
Risk & Volatility
Sotera Health has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Profitability
This table compares Sotera Health and Repligen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sotera Health | 14.11% | 38.46% | 7.66% |
| Repligen | -1.47% | 5.49% | 3.93% |
Insider and Institutional Ownership
91.0% of Sotera Health shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by insiders. Comparatively, 0.6% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Sotera Health and Repligen, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sotera Health | 1 | 2 | 8 | 0 | 2.64 |
| Repligen | 1 | 3 | 12 | 2 | 2.83 |
Sotera Health currently has a consensus target price of $20.88, indicating a potential upside of 28.07%. Repligen has a consensus target price of $178.57, indicating a potential upside of 7.24%. Given Sotera Health’s higher possible upside, equities research analysts plainly believe Sotera Health is more favorable than Repligen.
Valuation & Earnings
This table compares Sotera Health and Repligen”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sotera Health | $1.23 billion | 3.79 | $77.94 million | $0.60 | 27.17 |
| Repligen | $805.61 million | 13.21 | $48.89 million | ($0.21) | -792.95 |
Sotera Health has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
Summary
Sotera Health beats Repligen on 10 of the 15 factors compared between the two stocks.
About Sotera Health
Sotera Health Company is a global provider of sterilization, laboratory testing and advisory services for the medical device, pharmaceutical and food industries. Its services help customers assess product safety, meet regulatory requirements and prepare products for use. Through Sterigenics, the company provides contract sterilization using technologies including ethylene oxide, gamma irradiation and electron beam processing. Nelson Labs offers microbiological and analytical testing, as well as consulting, for medical devices and pharmaceutical products.
About Repligen
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
